Drug Trial Radar · NCT07150767
A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 26, 2025
Primary completion
Mar 26, 2027
Study completion Mar 26, 2027
Sponsor
- Lead sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical study to explore the safety, tolerability, and efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) combined with neoadjuvant treatment for locally advanced breast cancer.This study is a single-arm, open-label, single-center dose-escalation and expansion trial.
Conditions
- Locally Advanced Breast Cancer (LABC)
Interventions
BioTTT001 injectionBiological
BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 5.0×10\^10 viral particle (VP) ,2.0×10\^11 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: The DLT observation period for each subject is 21 days after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second People's Hospital of Shandong Province
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.